Business
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma\nPR Newswire\nREHOVOT, Israel and BETHESDA, MD, Nov. 8, 2022\n\n\n\nREHOVOT, Israel and BETHESDA, MD, Nov. 8, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related medicine, announced today that it has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company, and co-founder Prof. Benjamin Dekel (MD, PhD) will continue to serve as the company's Chief Scientist; CNBX Chairman, Gabriel Yariv, to assume the position of TaGeza Biopharmaceuticals CEO.\n\n \n \n \n \n \n \n\n \nTaGeza was founded in 2014 by a medical team from Sheba Medical Center, Israel's largest hospital, led by Prof. Benjamin Dekel (MD, PhD), and under a research collaboration agreement with the Sheba Medical Center.\nTaGeza is a developer of next generation immunotherapy and cancer-targeted therapies. The company is currently developing novel Antibody Drug Conjugates (ADCs) based on novel monoclonal antibodies (mAbs), targeting specific types of cancer by way of targeting the subpopulation of highly tumorigenic cancerous cells, known as Cancer Stem Cells (CSC) or Tumor Initiating Cells (TICs). Patients undergoing more conventional therapies such as chemotherapy enjoy a reduction in tumor size but can often relapse and even develop a more aggressive disease, in part due to the residual population of chemotherapy-resistant tumor cells are enriched by CSCs or TICs. Therefore, targeting CSCs/TICs can help improve patient outcome and reduce relapse caused by their aggressive self-renewal and tumorigenic properties as well as their resistance to more conventional therapies.\nThe usage ADC therapies is already well established, and growing, as they become increasingly noticeable in the oncolo...